# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Sean Dodge reiterates GoodRx Holdings (NASDAQ:GDRX) with a Outperform and maintains $10 price target.
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $11 ...
UBS analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $9 to $8.5.
GoodRx reported Q2 revenue of $200.61M, a 6% YoY increase. Prescription transactions revenue rose 7%, driven by 8% growth in Mo...
Guidance For the third quarter and full year 2024, management is anticipating the following: $ in millions ...
Guidance For the third quarter and full year 2024, management is anticipating the following: $ in millions ...
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0....
Boehringer Ingelheim and GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today a patien...